Ketamine Wellness Centers, a subsidiary of Delic Holdings, announces the grand opening of its 13th ketamine clinic.
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
Novamind announces it will most MindMed's Phase IIb clinical trial of LSD-based therapy for generalized anxiety disorder (GAD).
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
Enveric Bioscience announces the publishing of four PCT applications by the World Intellectual Property Organization.
Brain Injury Awareness Month: New Hope With Psychedelic Medicine
Thanks to the advance of psychedelic medicine, "brain injury awareness" is about more than highlighting a problem. It's also about new hope for sufferers.
Numinus Expands Natural Psychedelic Research with New Biosecurity License
Numinus announces that its Numinus Bioscience research lab has been approved for a Containment Level 2 (CL2) license from Health Canada.
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
Bright Minds Biosciences announced the successful completion of a 28-day toxicology study for BMB-101.
Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013
Wesana Health reports positive feedback from FDA on pre-IND meeting regarding development of SANA -013 and is anticipating commencing a clinical trial in Q4 2022.
Red Light Holland and Advocacy Group Psychedelic Medicine Alliance Washington Celebrate the Success of their Collaboration as Washington Legislature Funds Psilocybin Wellness Workgroup
Red Light Holland applauds the decision of Washington State's government to provide $200,000 in funding for psychedelics research.
Albert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading on the Canadian Securities Exchange
UK-based Albert Labs announces its official trading date on Canada's CSE exchange. The Company will commence trading Thursday, March 11th under the symbol "ABRT"
Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets
Small Pharma announces two more planned clinical trials for 2022 from its pipeline of DMT-based drug candidates.
Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies
Incannex reports a strong clinical response in its trial of a cannabinoid combination product IHL-42X for sleep apnea.
Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics
Incannex Healthcare to incorporate virtual reality in a new R&D partnership aimed at psychedelics-based therapies.
